Healthcare provider profile · identity verified

Blake Dixon, DO

Allopathic & Osteopathic Physicians|Family Medicine · SOMERSET, KY · NPI 1033772199

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Blake Dixon, DO received $50.90 in general payments during 2025 across 3 reported records.

Cipher Pharmaceuticals US LLC accounted for 39.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$50.90

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Cipher Pharmaceuticals US LLC	Unresolved — no canonical attribution shown	$20.25	39.8%	1	2025
Phathom Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$17.18	33.8%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$13.47	26.5%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$50.90	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Natroba Normalized: natroba	Drug	Cipher Pharmaceuticals US LLC	$20.25	1	2025
Source payment records 2025-06-24 · Cipher Pharmaceuticals US LLC · $20.25 · Open Payments source
Spinosad Normalized: spinosad	Drug	Cipher Pharmaceuticals US LLC	$20.25	1	2025
Source payment records 2025-06-24 · Cipher Pharmaceuticals US LLC · $20.25 · Open Payments source
VOQUEZNA Normalized: voquezna	Drug	Phathom Pharmaceuticals, Inc.	$17.18	1	2025
Source payment records 2025-04-23 · Phathom Pharmaceuticals, Inc. · $17.18 · Open Payments source
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$13.47	1	2025
Source payment records 2025-03-24 · ABBVIE INC. · $13.47 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$13.47	1	2025
Source payment records 2025-03-24 · ABBVIE INC. · $13.47 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	ARMOUR THYROID open payments reported associated product	CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088	Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	29	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	44	13

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	608	152
Omeprazole	Omeprazole	566	124
Levothyroxine Sodium	Levothyroxine Sodium	437	90
Lisinopril	Lisinopril	391	91
Amlodipine Besylate	Amlodipine Besylate	368	93
Losartan Potassium	Losartan Potassium	249	66
Gabapentin	Gabapentin	245	46
Pantoprazole Sodium	Pantoprazole Sodium	235	49
Rosuvastatin Calcium	Rosuvastatin Calcium	214	58
Simvastatin	Simvastatin	204	48
Metformin Hcl	Metformin Hcl	194	57
Hydrochlorothiazide	Hydrochlorothiazide	188	53
Furosemide	Furosemide	184	56
Sertraline Hcl	Sertraline Hcl	182	41
Ozempic	Semaglutide	181	26
Tamsulosin Hcl	Tamsulosin Hcl	174	48
Fluticasone Propionate	Fluticasone Propionate	167	82
Meloxicam	Meloxicam	161	49
Montelukast Sodium	Montelukast Sodium	156	38
Citalopram Hbr	Citalopram Hydrobromide	153	31
Metoprolol Succinate	Metoprolol Succinate	153	42
Trazodone Hcl	Trazodone Hcl	150	34
Albuterol Sulfate Hfa	Albuterol Sulfate	148	37
Metoprolol Tartrate	Metoprolol Tartrate	140	40
Prednisone	Prednisone	140	100
Buspirone Hcl	Buspirone Hcl	138	36
Famotidine	Famotidine	134	31
Alprazolam	Alprazolam	129	23
Azithromycin	Azithromycin	129	120
Duloxetine Hcl	Duloxetine Hcl	129	34
Metformin Hcl Er	Metformin Hcl	128	35
Potassium Chloride	Potassium Chloride	127	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	119	35
Pravastatin Sodium	Pravastatin Sodium	119	30
Carvedilol	Carvedilol	115	27
Eliquis	Apixaban	112	25
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	108	100
Mounjaro	Tirzepatide	105	16
Clonazepam	Clonazepam	103	12
Tramadol Hcl	Tramadol Hcl	102	28
Atenolol	Atenolol	100	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	92	46
Clopidogrel	Clopidogrel Bisulfate	91	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	90	19
Amitriptyline Hcl	Amitriptyline Hcl	87	22
Bupropion Xl	Bupropion Hcl	85	18
Spironolactone	Spironolactone	84	17
Ezetimibe	Ezetimibe	79	19
Triamcinolone Acetonide	Triamcinolone Acetonide	78	40
Isosorbide Mononitrate Er	Isosorbide Mononitrate	76	16
Valsartan	Valsartan	76	20
Esomeprazole Magnesium	Esomeprazole Magnesium	69	14
Pregabalin	Pregabalin	67	13
Venlafaxine Hcl Er	Venlafaxine Hcl	66	14
Diclofenac Sodium	Diclofenac Sodium	65	31
Escitalopram Oxalate	Escitalopram Oxalate	65	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	65	20
Fluconazole	Fluconazole	64	40
Olmesartan Medoxomil	Olmesartan Medoxomil	63	19
Celecoxib	Celecoxib	62	16
Alendronate Sodium	Alendronate Sodium	60	16
Januvia	Sitagliptin Phosphate	60	14
Methocarbamol	Methocarbamol	59	17
Doxycycline Hyclate	Doxycycline Hyclate	58	53
Oxybutynin Chloride Er	Oxybutynin Chloride	57	12
Finasteride	Finasteride	55	11
Mupirocin	Mupirocin	55	37
Temazepam	Temazepam	54	suppressed
Jardiance	Empagliflozin	49	suppressed
Allopurinol	Allopurinol	48	suppressed
Amoxicillin	Amoxicillin	48	45
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	48	14
Warfarin Sodium	Warfarin Sodium	48	suppressed
Baclofen	Baclofen	47	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	47	11
Farxiga	Dapagliflozin Propanediol	47	14
Promethazine Hcl	Promethazine Hcl	47	19
Ondansetron Odt	Ondansetron	45	24
Donepezil Hcl	Donepezil Hcl	44	16
Hydroxyzine Hcl	Hydroxyzine Hcl	44	12
Oxycodone Hcl	Oxycodone Hcl	44	13
Synthroid	Levothyroxine Sodium	44	13
Fluoxetine Hcl	Fluoxetine Hcl	43	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	43	40
Quetiapine Fumarate	Quetiapine Fumarate	43	suppressed
Trulicity	Dulaglutide	43	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	41	suppressed
Levetiracetam	Levetiracetam	41	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	40	suppressed
Ibuprofen	Ibuprofen	39	19
Ropinirole Hcl	Ropinirole Hcl	39	11
Tizanidine Hcl	Tizanidine Hcl	39	12
Valacyclovir	Valacyclovir Hcl	37	13
Nystatin	Nystatin	36	16
Ventolin Hfa	Albuterol Sulfate	36	suppressed
Diazepam	Diazepam	33	suppressed
Primidone	Primidone	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	15
Cefdinir	Cefdinir	31	30
Naproxen	Naproxen	31	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Linzess	Linaclotide	29	suppressed
Meclizine Hcl	Meclizine Hcl	29	12
Hydralazine Hcl	Hydralazine Hcl	28	suppressed
Clonidine Hcl	Clonidine Hcl	27	suppressed
Glipizide	Glipizide	27	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	27	suppressed
Tradjenta	Linagliptin	27	suppressed
Glimepiride	Glimepiride	26	suppressed
Topiramate	Topiramate	25	suppressed
Acyclovir	Acyclovir	24	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	24	suppressed
Cephalexin	Cephalexin	24	23
Ranolazine Er	Ranolazine	24	suppressed
Xarelto	Rivaroxaban	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	19
Midodrine Hcl	Midodrine Hcl	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Theophylline Er	Theophylline Anhydrous	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	20	suppressed
Verapamil Er	Verapamil Hcl	20	suppressed
Zonisamide	Zonisamide	20	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	18	suppressed
Azelastine Hcl	Azelastine Hcl	18	14
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	18	suppressed
Repatha Sureclick	Evolocumab	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	14
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	17	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Phenobarbital	Phenobarbital	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Amantadine	Amantadine Hcl	15	suppressed
Armour Thyroid	Thyroid,pork	15	suppressed
Flecainide Acetate	Flecainide Acetate	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Naratriptan Hcl	Naratriptan Hcl	14	suppressed
Anastrozole	Anastrozole	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Nurtec Odt	Rimegepant Sulfate	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rexulti	Brexpiprazole	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Brilinta	Ticagrelor	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	11
Dilt-Xr	Diltiazem Hcl	12	suppressed
Glyburide	Glyburide	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Trimethoprim	Trimethoprim	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Colchicine	Colchicine	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Roflumilast	Roflumilast	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Triumeq	Abacavir/Dolutegravir/Lamivudi	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$50.90 · 3 records	Cipher Pharmaceuticals US LLC	Natroba, QULIPTA, Spinosad, UBRELVY, VOQUEZNA	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error